[Featured Stock] SK Biopharm Leading with 'Cenobamate' Hits Consecutive 52-Week Highs... Market Cap Approaching 10 Trillion Won

Strong Performance of 'Cenobamate' Drives Stock Price Increase
Q2 Revenue 134 Billion KRW, First 3 Consecutive Quarters of Profit Since Establishment
Brokerage Firms Forecast Upward Trend in SK Biopharm Operating Profit

SK Biopharm continues its 52-week high rally day after day. The strong performance led by the epilepsy drug 'Cenobamate' and future expectations seem to be reflected in the stock price.

As of 9:26 AM on the 29th, SK Biopharm is trading at 118,900 KRW, up 5.04% (5,700 KRW) from the previous day. On the 16th, SK Biopharm's stock price broke through the 100,000 KRW mark for the first time in about seven months, setting a 52-week high. After fluctuating within the 100,000 to 110,000 KRW range, it has turned upward. The current market capitalization is approximately 9.28 trillion KRW, making the '10 trillion club' also within sight.

SK Biopharm's new drug Cenobamate is credited as the main driver of improved performance. In the second quarter, Cenobamate's sales in the U.S. amounted to 105.2 billion KRW, a 65% increase compared to the previous year. As a result, SK Biopharm recorded 134 billion KRW in sales and 26 billion KRW in operating profit in the second quarter, continuing its first-ever three consecutive quarters of profit since its founding.

Lee Seon-kyung, a researcher at SK Securities, said, "SK Biopharm, which has low recognition in the U.S., is growing rapidly," adding, "It is said to be more effective compared to competing products approved in the last 10 years. The performance improvement due to the success of Cenobamate is expected to continue. According to the consensus (market average forecast) in the securities industry, SK Biopharm, which posted a 37.5 billion KRW loss last year, is expected to record operating profits of 80.1 billion KRW this year and 183 billion KRW next year."